Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan.

Learn more about:
Related Clinical Trial
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.

Official Title

Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.

Brief Summary

      The purpose of this long-term study is to determine whether Zinc Acetate is effective and
      safe in the treatment of Wilson's disease among Japanese.
    

Detailed Description

      Wilson disease is an autosomal recessive disorder with copper metabolism. In Japan, the
      standard treatment is the use of copper chelating agents, such as D-penicillamine and
      trientine. In this study, we investigate efficacy on zinc acetate in Japanese patients with
      Wilson disease.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Safety and Efficacy


Condition

Wilson's Disease

Intervention

NPC-02

Study Arms / Comparison Groups

 NPC-02
Description:  zinc acetate

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

37

Start Date

March 2005

Completion Date

January 2009

Primary Completion Date

April 2008

Eligibility Criteria

        Inclusion Criteria:

          -  Wilson's disease(adult, infant, pregnant woman)

        Exclusion Criteria:

          -  Acute hepatitis

          -  Malignant tumor
      

Gender

All

Ages

1 Year - N/A

Accepts Healthy Volunteers

No

Contacts

Koudou Ishii, M.D., , 



Administrative Informations


NCT ID

NCT00212355

Organization ID

NPC-02-2


Responsible Party

Sponsor

Study Sponsor

Nobelpharma


Study Sponsor

Koudou Ishii, M.D., Study Director, National MINAMIYOKOHAMA Hospital


Verification Date

April 2019